About
About Beijing Strong Biotechnologies, Inc
Beijing Strong Biotechnologies,Inc. researches, develops, manufactures, and sells in-vitro diagnostics (IVD) products and services in China and internationally. It provides biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein S activity, protein C, lupus anticoagulant, fibrin degradation products, and d-dimer. The company also offers blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; and automatic coagulation analyzer, automatic biochemistry analyzer, fully automatic chemiluminescence immunoassay analyzer, and automated blood groupings analyzer. It sells its products under the Kingsley and Meichuang brand names. Beijing Strong Biotechnologies,Inc. was founded in 2001 and is based in Beijing, China.
Research context
Beijing Strong Biotechnologies, Inc appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Beijing Strong Biotechnologies, Inc is currently in a long term downtrend where the price is trading 2.0% below its 200 day moving average.
From a valuation standpoint, the stock is 25.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.1.
Beijing Strong Biotechnologies, Inc's total revenue sank by 2.9% to $262M since the same quarter in the previous year.
Its net income has dropped by 53.1% to $53M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.8% to $32M since the same quarter in the previous year.
Based on the above factors, Beijing Strong Biotechnologies, Inc gets an overall score of 0/5.